Javier Fernández-Ruiz

Universidad Complutense de Madrid

Spain

Research Interests

Explore related searches

Professors in Spain

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (20)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Collaborators (12)

Roger Schibli

Prof. at ETH Zürich

ETH Zürich

SWITZERLAND

View details

María Gómez Cañas

Profesora Ayudante Doctor

Universidad Complutense de Madrid Facultad de Medicina

SPAIN

View details

Jose Lanciego

Staff Scientist & Associate Professor

SPAIN

View details

Amalia Diez

PROFESOR TITULAR

Universidad Complutense de Madrid

SPAIN

View details

Diego Caprioglio

Lecturer

Università degli Studi del Piemonte Orientale

ITALY

View details

Patricia Marin-Garcia

Universidad Rey Juan Carlos

SPAIN

View details

ONINTZA SAGREDO EZQUIOGA

Profesora Titular

Universidad Complutense de Madrid

SPAIN

View details

EVA DE LAGO

Profesor Titular

Universidad Complutense de Madrid

SPAIN

View details

Carmen Rodriguez Cueto

Assistant Professor

Universidad Complutense de Madrid

SPAIN

View details

Mitchell P. Croatt

University of North Carolina at Greensboro

UNITED STATES

View details

Manuel Guzmán

Universidad Complutense de Madrid

SPAIN

View details

Dmitry Veprintsev

Professor of Molecular and Cellular Pharmacology

University of Nottingham

UNITED KINGDOM

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Javier Fernández-Ruiz

Research Interests

Explore related searches

Contact this professor

Articles (20)

Preclinical evaluation of cannabidiolic acid as a neuroprotective agent in TDP-43 transgenic mice, an experimental model of amyotrophic lateral sclerosis

Ageing, Neurodegeneration and the Endocannabinoid System.

Neurodegenerative Diseases: Pathogenesis and Preclinical Models for Translational Drug Discovery.

Investigation in the CB1 and CB2 receptor binding profile and intrinsic activity of (-) and (+)-enantiomers of some naturally occurring phytocannabinoids or synthetic derivatives

Investigation in blood-brain barrier integrity and susceptibility to immune cell penetration in a mouse model of Dravet syndrome

Preclinical Assessment of a Cannabinoid CB2 Receptor Antagonist in a Murine Model of Cerebral Malaria

Investigation in the cannabigerol derivative VCE-003.2 as a disease-modifying agent in a mouse model of experimental synucleinopathy

Beneficial Effect of Dimethyl Fumarate Drug Repositioning in a Mouse Model of TDP-43-Dependent Frontotemporal Dementia

Enhancing Drug Discovery and Development through the Integration of Medicinal Chemistry, Chemical Biology, and Academia-Industry Partnerships: Insights from Roche's Endocannabinoid System Projects.

Involvement of CB<sub>1</sub> and CB<sub>2</sub> receptors in neuroprotective effects of cannabinoids in experimental TDP-43 related frontotemporal dementia using male mice.

Preclinical investigation in FAAH inhibition as a neuroprotective therapy for frontotemporal dementia using TDP-43 transgenic male mice

The Cannabigerol Derivative VCE-003.2 Exerts Therapeutic Effects in 6-Hydroxydopamine-Lesioned Mice: Comparison with The Classic Dopaminergic Replacement Therapy

Thienopyrimidine Derivatives as GPR55 Receptor Antagonists: Insight into Structure–Activity Relationship

Disease-modifying effects of cannabidiol, β-caryophyllene and their combination in Syn1-Cre/Scn1aWT/A1783V mice, a preclinical model of Dravet syndrome

Endocannabinoid-Binding Receptors as Drug Targets.

Preclinical investigation of β-caryophyllene as a therapeutic agent in an experimental murine model of Dravet syndrome

New Statement about NRF2 in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia

Preclinical Investigation in Neuroprotective Effects of the GPR55 Ligand VCE-006.1 in Experimental Models of Parkinson’s Disease and Amyotrophic Lateral Sclerosis

BiP Heterozigosity Aggravates Pathological Deterioration in Experimental Amyotrophic Lateral Sclerosis

Cannabinoid receptor CB2 ablation protects against TAU induced neurodegeneration

Collaborators (12)

Roger Schibli

María Gómez Cañas

Jose Lanciego

Amalia Diez

Diego Caprioglio

Patricia Marin-Garcia

ONINTZA SAGREDO EZQUIOGA

EVA DE LAGO

Carmen Rodriguez Cueto

Mitchell P. Croatt

Manuel Guzmán

Dmitry Veprintsev

Make your next move.

Javier Fernández-Ruiz

Research Interests

Explore related searches

Contact this professor

Articles (20)

Preclinical evaluation of cannabidiolic acid as a neuroprotective agent in TDP-43 transgenic mice, an experimental model of amyotrophic lateral sclerosis

Ageing, Neurodegeneration and the Endocannabinoid System.

Neurodegenerative Diseases: Pathogenesis and Preclinical Models for Translational Drug Discovery.

Investigation in the CB1 and CB2 receptor binding profile and intrinsic activity of (-) and (+)-enantiomers of some naturally occurring phytocannabinoids or synthetic derivatives

Investigation in blood-brain barrier integrity and susceptibility to immune cell penetration in a mouse model of Dravet syndrome

Preclinical Assessment of a Cannabinoid CB2 Receptor Antagonist in a Murine Model of Cerebral Malaria

Investigation in the cannabigerol derivative VCE-003.2 as a disease-modifying agent in a mouse model of experimental synucleinopathy

Beneficial Effect of Dimethyl Fumarate Drug Repositioning in a Mouse Model of TDP-43-Dependent Frontotemporal Dementia

Enhancing Drug Discovery and Development through the Integration of Medicinal Chemistry, Chemical Biology, and Academia-Industry Partnerships: Insights from Roche's Endocannabinoid System Projects.

Involvement of CB<sub>1</sub> and CB<sub>2</sub> receptors in neuroprotective effects of cannabinoids in experimental TDP-43 related frontotemporal dementia using male mice.

Preclinical investigation in FAAH inhibition as a neuroprotective therapy for frontotemporal dementia using TDP-43 transgenic male mice

The Cannabigerol Derivative VCE-003.2 Exerts Therapeutic Effects in 6-Hydroxydopamine-Lesioned Mice: Comparison with The Classic Dopaminergic Replacement Therapy

Thienopyrimidine Derivatives as GPR55 Receptor Antagonists: Insight into Structure–Activity Relationship

Disease-modifying effects of cannabidiol, β-caryophyllene and their combination in Syn1-Cre/Scn1aWT/A1783V mice, a preclinical model of Dravet syndrome

Endocannabinoid-Binding Receptors as Drug Targets.

Preclinical investigation of β-caryophyllene as a therapeutic agent in an experimental murine model of Dravet syndrome

New Statement about NRF2 in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia

Preclinical Investigation in Neuroprotective Effects of the GPR55 Ligand VCE-006.1 in Experimental Models of Parkinson&rsquo;s Disease and Amyotrophic Lateral Sclerosis

BiP Heterozigosity Aggravates Pathological Deterioration in Experimental Amyotrophic Lateral Sclerosis

Cannabinoid receptor CB2 ablation protects against TAU induced neurodegeneration

Collaborators (12)

Roger Schibli

María Gómez Cañas

Jose Lanciego

Amalia Diez

Diego Caprioglio

Patricia Marin-Garcia

ONINTZA SAGREDO EZQUIOGA

EVA DE LAGO

Carmen Rodriguez Cueto

Mitchell P. Croatt

Manuel Guzmán

Dmitry Veprintsev

Make your next move.

Preclinical Investigation in Neuroprotective Effects of the GPR55 Ligand VCE-006.1 in Experimental Models of Parkinson’s Disease and Amyotrophic Lateral Sclerosis